Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Webinar Series: Sickle Cell Science: Path to Progress – Serving the Sickle Cell Disease Community Here and Abr...To commemorate Sickle Cell Awareness Mon...
-
Practice variation in emergency department management of children with sickle cell disease who present with feverOBJECTIVES:Urgent medical evaluation is ...
-
Gaurav Kharya MBBS, DNB, DCHDr. Gaurav Kharya is a Clinical Lead at ...
-
Association Between Hospital Admissions and Healthcare Provider Communication for Individuals With Sickle Cell Disea...Objective: To test the hypothesis that ...
-
Our Healthcare System Abandons Adult Sickle Cell PatientsWhen Janoi Burgess was a child, he thoug...
-
UT Southwestern Medical CenterUT Southwestern Medical Center is a lead...
-
6th Annual Chicago Sickle Cell SummitDate & Time Sep 28, 2023 11:00 AM...